Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod

• Hauptverfasser: Qiudi Jiang (Verfasst von), Yuchen Zhang (Verfasst von), Dan Duan (Verfasst von), Sylvie Retout (Verfasst von), Ruchi Upmanyu (Verfasst von), Katerina Glavini (Verfasst von), Miriam Triyatni (Verfasst von), Yonghong Zhu (Verfasst von), Joseph F. Grippo (Verfasst von), Yuyan Jin (Verfasst von)
• Format: Buch
• Veröffentlicht: Wiley, 2024-08-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract Ruzotolimod (Toll‐like receptor 7 (TLR7) agonist, RG7854) is an oral, small molecule immuno‐modulator activating the TLR 7 and is being evaluated in patients with CHB. As with other TLR7 agonists, the study drug‐related adverse events of flu‐like symptoms have been reported in some particip...